The potential and promise of mefenamic acid

Expert Review of Clinical Pharmacology

Volumn 6, Issue 3, 2013, Pages 289-305

  Cimolai, Nevio ^a  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

analgesia; anti inflammatory; mefenamic acid; pharmacology; toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; CODEINE; CYCLOSPORIN; DANAZOL; DEXTROPROPOXYPHENE; DICLOFENAC; DIFLUNISAL; DRUG METABOLITE; ETORICOXIB; FENOPROFEN; IBUPROFEN; INDOMETACIN; IODINE; KAOLIN; KETOPROFEN; LITHIUM; MAGNESIUM HYDROXIDE; MEFENAMIC ACID; MELOXICAM; NAPROXEN; PARACETAMOL; PIROXICAM; TRANEXAMIC ACID; VALPROIC ACID; ZOMEPIRAC;

ABDOMINAL PAIN; ALLERGIC REACTION; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ASTHMA; BACKACHE; BLOATING; BLURRED VISION; BONE PAIN; BRONCHOSPASM; BULLOUS PEMPHIGOID; CHRONIC PAIN; COLLES FRACTURE; CONSTIPATION; CYTOTOXICITY; DEPRESSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRY EYE; DYSMENORRHEA; ENDODONTIC PAIN; ENTEROPATHY; ENZYME INHIBITION; EPIGASTRIC PAIN; ESOPHAGUS ULCER; EXTRAPYRAMIDAL SYMPTOM; FEVER; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOMODULATION; INSOMNIA; INTERSTITIAL NEPHRITIS; LEG EDEMA; LINEAR IGA BULLOUS DERMATOSIS; MENORRHAGIA; METASTASIS INHIBITION; MIGRAINE; MOUTH CANCER; MYALGIA; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; NEUROPATHIC PAIN; NEUTROPENIA; NIGHTMARE; NONHUMAN; OSTEOARTHRITIS; PAIN; PANCREATITIS; POSTOPERATIVE PAIN; PREMENSTRUAL SYNDROME; PROCTOCOLITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOFT TISSUE DISEASE; STEVENS JOHNSON SYNDROME; STOMACH EROSION; STOMACH ULCER; TENSION HEADACHE; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VENOUS THROMBOEMBOLISM; VERTIGO; VOMITING; XEROSTOMIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; FENAMATES; HUMANS; MEFENAMIC ACID; PAIN;

EID: 84877605895     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.13.15     Document Type: Review

References (241)

1. Winder CV. Experimental observations on flufenamic, mefenamic, and meclofenamic acids. I. Pharmacology. Ann. Phys. Med. 7-16 (1966).
2. Ziel R, Krupp P. The significance of inhibition of prostaglandin synthesis in the selection of non-steroidal antiinflammatory agents. Int. J. Clin. Pharmacol. Biopharm. 12(1-2), 186-191 (1975).
3. No authors listed. Mefenamic acid. Med. Lett. Drugs Ther. 9, 77-78 (1967).
4. Keys J, Beardon PH, Lau C, Lang CC, McDevitt DG. General practitioners' use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions. J. R. Soc. Med. 85(8), 442-445 (1992).
5. Long CC, Finlay AY, Marks R. Fixed drug eruption to mefenamic acid: a report of three cases. Br. J. Dermatol. 126(4), 409-411 (1992).
6. Ferrando C, Henman MC, Corrigan OI. Impact of a nationwide limited prescribing list: preliminary findings. Drug Intell. Clin. Pharm. 21(7-8), 653-658 (1987).
7. Gaganis P, Miners JO, Knights KM. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem. Pharmacol. 73(10), 1683-1691 (2007).
8. Dhabali AA, Awang R, Hamdan Z, Zyoud SH. Associations between prescribing nonsteroidal anti-inflammatory drugs and the potential prescription-related problems in a primary care setting. Int. J. Clin. Pharmacol. Ther. 50(12), 851-861 (2012).
9. Jones OA, Voulvoulis N, Lester JN. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 36(20), 5013-5022 (2002).
10. Azzouz A, Jurado-Sánchez B, Souhail B, Ballesteros E. Simultaneous determination of 20 pharmacologically active substances in cow's milk, goat's milk, and human breast milk by gas chromatography-mass spectrometry. J. Agric. Food Chem. 59(9), 5125-5132 (2011).
11. Taylor D, Clark DW, Dovey SM, Tilyard MW. The prescribing and adverse reactions of nonsteroidal anti-inflammatory drugs in general practice: a Dunedin study. N. Z. Med. J. 107(981), 263-266 (1994).
12. Künzel AR, Haschke M, Surber C, Lambrecht JT. [Mefenaminsäure und andere NSAR in der zahnärztlichen Praxis.] Schweiz. Monatsschr. Zahnmed. 117, 12-18 (2007).
13. Hixson LJ, Alberts DS, Krutzsch M et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 3(5), 433-438 (1994).
14. Akatsu T, Catanzaro Guimarães SA. Comparative effects of non-steroidal anti-inflammatory drugs, mefenamic acid, metiazinic acid and glucametacin on the inflammatory response induced by subcutaneous implantation of human dental plaque and on the mitotic activity of isoproterenol-stimulated parotid glands of rats. Cell. Mol. Biol. 32(5), 619-626 (1986).
15. Newcombe DS, Thanassi NM, Ciosek CP Jr. Cartilage cyclic nucleotide phosphodiesterase: inhibition by anti-inflammatory agents. Life Sci. 14(3), 505-519 (1974).
16. Mavrikakis ME, Madkour MM, Buchanan WW. The place of mefenamic acid in the treatment of rheumatoid arthritis. Scott. Med. J. 23(2), 189-190 (1978).
17. Lora M, Denault JB, Leduc R, de Brum-Fernandes AJ. Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot. Essent. Fatty Acids 59(1), 55-62 (1998).
18. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104(5), 413-421 (1998).
19. Gierse JK, Hauser SD, Creely DP et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305 (Pt 2), 479-484 (1995).
20. Laudanno OM, Cesolari JA, Esnarriaga J, San Miguel P, Bedini OA. In vivo selectivity of nonsteroidal antiinflammatory drugs and gastrointestinal ulcers in rats. Dig. Dis. Sci. 45(7), 1359-1365 (2000).
21. Mullink H, von Blomberg M. Influence of anti-inflammatory drugs on the interaction of lymphocytes and macrophages. Agents Actions 10(6), 512-515 (1980).
22. Kowalczyk-Bronisz SH, Gieldanowski J. Activity of nonsteroid anti-inflammatory drugs in immunologically specific and nonspecific cellular responses. Arch. Immunol. Ther. Exp. (Warsz.) 24(1), 149-157 (1976).
23. Ruutu T, Kosunen TU. In vitro effect of anti-inflammatory agents on phagocytosis and bacterial killing by human neutrophilic leukocytes. Acta Pharmacol. Toxicol. (Copenh). 31(3), 226-237 (1972).
24. Wojnar RJ, Hearn T, Starkweather S. Augmentation of allergic histamine release from human leukocytes by nonsteroidal anti-inflammatory-analgesic agents. J. Allergy Clin. Immunol. 66(1), 37-45 (1980).
25. Zucker MB, Peterson J. Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents, and dipyridamole on human blood platelets. J. Lab. Clin. Med. 76(1), 66-75 (1970).
26. Bailey JM, Makheja AN, Butler J, Salata K. Anti-inflammatory drugs in experimental atherosclerosis. Part 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vitro. Atherosclerosis 32(2), 195-203 (1979).
27. Bailey JM, Butler J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis 17(3), 515-522 (1973).
28. Cryer HM, Unger LS, Garrison RN, Harris PD. Prostaglandins maintain renal microvascular blood flow during hyperdynamic bacteremia. Circ. Shock 26(1), 71-88 (1988).
29. Schölkens BA, Steinbach R. Increase of experimental hypertension following inhibition of prostaglandin biosynthesis. Arch. Int. Pharmacodyn. Ther. 214(2), 328-334 (1975).
30. Halliwell RF, Thomas P, Patten D et al. Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid. Eur. J. Neurosci. 11(8), 2897-2905 (1999).
31. Khansari PS, Halliwell RF. Evidence for neuroprotection by the fenamate NSAID, mefenamic acid. Neurochem. Int. 55(7), 683-688 (2009).
32. Chen Q, Olney JW, Lukasiewicz PD, Almli T, Romano C. Fenamates protect neurons against ischemic and excitotoxic injury in chick embryo retina. Neurosci. Lett. 242(3), 163-166 (1998).
33. López-Villodres JA, De La Cruz JP, Muñoz-Marin J, Guerrero A, Reyes JJ, González-Correa JA. Cytoprotective effect of nonsteroidal antiinflammatory drugs in rat brain slices subjected to reoxygenation after oxygen-glucose deprivation. Eur. J. Pharm. Sci. 45(5), 624-631 (2012).
34. Karmazyn M, Pierce GN, Williams S. Effect of nonsteroidal anti-inflammatory drugs on the hypoxic rat heart. J. Pharmacol. Exp. Ther. 218(2), 488-496 (1981).
35. Kelly JJ, Auer RN. Mefenamate, an agent that fails to attenuate experimental cerebral infarction. Can. J. Neurol. Sci. 30(3), 259-262 (2003).
36. Ikonomidou-Turski C, Cavalheiro EA, Turski L et al. Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats. Brain Res. 462(2), 275-285 (1988).
37. Joo Y, Kim HS, Woo RS et al. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol. Pharmacol. 69(1), 76-84 (2006).
38. Glazko AJ. Experimental observations on flufenamic, mefenamic and meclofenamic acids. 3. Metabolic disposition. Ann. Phys. Med. VIII (Suppl. 1), 23-36 (1966).
39. Tall AR, Mistilis SP. Studies on Ponstan (mefenamic acid): I. Gastro-intestinal blood loss; II. Absorbtion and excretion of a new formulation. J. Int. Med. Res. 3(3), 176-182 (1975).
40. Leemann TD, Tanson C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Exp. Clin. Res. 19(5), 189-195 (1993).
41. McGurk KA, Remmel RP, Hosagrahara VP, Tosh D, Burchell B. Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab. Dispos. 24(8), 842-849 (1996).
42. Hamaguchi T, Shinkuma D, Yamanaka Y, Mizuno N. Bioavailability of mefenamic acid: influence of food and water intake. J. Pharm. Sci. 75(9), 891-893 (1986).
43. Qamar S, Irfan N, Ahmad M, Jamshaid M, Muzaffar NA. The bioavailability and pharmacokinetics of mefenamic acid in alloxan-diabetic rabbits. Tokai J. Exp. Clin. Med. 22(4), 163-166 (1997).
44. Hamaguchi T, Shinkuma D, Yamanaka Y, Mizuno N. Effects of food on absorption of mefenamic acid from two commercial capsules differing in bioavailability under the fasting state. J. Pharmacobio dyn. 10(1), 21-25 (1987).
45. Adam A, Schrimpl L, Schmidt PC. Some physicochemical properties of mefenamic acid. Drug Dev. Ind. Pharm. 26(5), 477-487 (2000).
46. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The 'high solubility' definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm. Res. 21(2), 293-299 (2004).
47. Corry D, Moran J. Assessment of acrylic bone cement as a local delivery vehicle for the application of non-steroidal antiinflammatory drugs. Biomaterials 19(14), 1295-1301 (1998).
48. Panchagnula R, Sundaramurthy P, Pillai O, Agrawal S, Raj YA. Solid-state characterization of mefenamic acid. J. Pharm. Sci. 93(4), 1019-1029 (2004).
49. Rasheed A, Ashok Kumar CK. Tyrosine and glycine derivatives as potential prodrugs: design, synthesis, and pharmacological evaluation of amide derivatives of mefenamic acid. J. Enzyme Inhib. Med. Chem. 25(6), 804-811 (2010).
50. Jilani JA, Najib NM, Ghariabeh SH. Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. Acta Pharm. Hung. 67(2-3), 99-104 (1997).
51. Ahmed TA, Ibrahim HM, Ibrahim F, Samy AM, Fetoh E, Nutan MT. In vitro release, rheological, and stability studies of mefenamic acid coprecipitates in topical formulations. Pharm. Dev. Technol. 16(5), 497-510 (2011).
52. Heard CM, Screen C. Probing the permeation enhancement of mefenamic acid by ethanol across full thickness skin, heat-separated epidermal membrane and heat-separated dermal membrane. Int. J. Pharm. 349(1-2), 323-325 (2008).
53. Alafeefy AM. Synthesis, analgesic and anti inflammatory activities of some new fenamate analogues. Arzneimittelforschung 58(9), 457-463 (2008).
54. Chhabria MT, Shishoo CJ, Vaghela DK, Patel SM, Satia MC. Design, synthesis and pharmacological evaluation of a series of 5-carbethoxy-4-chloro-6- (substituted amino)pyrimidines as potential analgesic and anti-flammatory agents with very low ulcerogenic potential. Arzneimittelforschung 59(7), 350-356 (2009).
55. Jakubowicz DL, Godard E, Dewhurst J. The treatment of premenstrual tension with mefenamic acid: analysis of prostaglandin concentrations. Br. J. Obstet. Gynaecol. 91(1), 78-84 (1984).
56. Wood C, Jakubowicz D. The treatment of premenstrual symptoms with mefenamic acid. Br. J. Obstet. Gynaecol. 87(7), 627-630 (1980).
57. Gunston KD. Premenstrual syndrome in Cape Town. Part II. A double-blind placebo-controlled study of the efficacy of mefenamic acid. S. Afr. Med. J. 70(3), 159-160 (1986).
58. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst. Rev.1, CD000400 (2010).
59. Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J, Markham R. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet. Gynecol. 58(5), 543-551 (1981).
60. Grover V, Usha R, Gupta U, Kalra S. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia. Oceania. J. Obstet. Gynaecol. 16(3), 255-259 (1990).
61. Grant C, Gallier L, Fahey T, Pearson N, Sarangi J. Management of menorrhagia in primary care -impact on referral and hysterectomy: data from the Somerset Morbidity Project. J. Epidemiol. Community Health 54(9), 709-713 (2000).
62. Haynes PJ, Flint AP, Hodgson H, Anderson AB, Dray F, Turnbull AC. Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations. Int. J. Gynaecol. Obstet. 17(6), 567-572 (1980).
63. van Eijkeren MA, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am. J. Obstet. Gynecol. 166(5), 1419-1428 (1992).
64. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust. N. Z. J. Obstet. Gynaecol. 31(1), 66-70 (1991).
65. Hall P, Maclachlan N, Thorn N, Nudd MW, Taylor CG, Garrioch DB. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br. J. Obstet. Gynaecol. 94(6), 554-558 (1987).
66. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br. J. Obstet. Gynaecol. 96(7), 840-844 (1989).
67. Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br. J. Obstet. Gynaecol. 98(7), 707-711 (1991).
68. Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet. Gynecol. 76(1), 85-88 (1990).
69. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 112(8), 1121-1125 (2005).
70. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 313(7057), 579-582 (1996).
71. Vairojanavong K, Limchitti D, Sasivimolkul V. Clinical trial of the efficacy of mefenamic acid in relief of menorrhagia and/or dysmenorrhoea. J. Med. Assoc. Thai. 66(2), 99-105 (1983).
72. Fraser IS, McCarron G, Markham R, Resta T, Watts A. Measured menstrual blood loss in women with menorrhagia associated with pelvic disease or coagulation disorder. Obstet. Gynecol. 68(5), 630-633 (1986).
73. Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long-term treatment of menorrhagia with mefenamic acid. Obstet. Gynecol. 61(1), 109-112 (1983).
74. Tsang BK, Domingo MT, Spence JE, Garner PR, Dudley DK, Oxorn H. Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. Can. J. Physiol. Pharmacol. 65(10), 2081-2084 (1987).
75. Cass LJ, Frederik WS. Experiments in relief of clinical pain with N-(2,3-xylyl)-anthranilic acid (CI-473; mefenamic acid). J. Pharmacol. Exp. Ther. 139, 172-176 (1963).
76. Haward LRC. Effects of the fenamates on the threshold of pain. Ann. Phys. Med. Suppl. 55-57 (1966).
77. Pulkkinen MO, Kaihola HL. Mefenamic acid in dysmenorrhea. Acta Obstet. Gynecol. Scand. 56(1), 75-76 (1977).
78. Kintis GA, Coutifaris B. Treatment of primary dysmenorrhea with mefenamic acid. Int. J. Gynaecol. Obstet. 18(3), 172-175 (1980).
79. Budoff PW. Treatment of dysmenorrhea. Am. J. Obstet. Gynecol. 129(2), 232 (1977).
80. Dreher E, von Fischer B. Treatment of primary dysmenorrheal and dysmenorrhea because of IUP with PG-synthetase inhibitors. Adv. Prostglandin Thromboxane Res. 8, 1487-1493 (1980).
81. Langrick AF, Gunn ADG, Livesey H, Whitehead AM. A double-blind placebocontrolled crossover study of mebeverine and mefenamic acid in the treatment of primary dysmenorrheal. Br. J. Clin. Pract. 43(9), 317-321 (1989).
82. Tilyard MW, Dovey SM. A comparison of tiaprofenic acid, mefenamic acid and placebo in the treatment of dysmenorrhoea in general practice. Aust. N. Z. J. Obstet. Gynaecol. 32(2), 165-168 (1992).
83. Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA 241(25), 2713-2716 (1979).
84. Roy S. A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet. Gynecol. 61(5), 628-632 (1983).
85. Namavar JB, Tartifizadeh A, Khabnadideh S. Comparison of fennel and mefenamic acid for the treatment of primary dysmenorrhea. Int. J. Gynaecol. Obstet. 80(2), 153-157 (2003).
86. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am. J. Obstet. Gynecol. 148(1), 96-103 (1984).
87. Aylward M, Maddock J, Lewis PA, Dewland PM. Mefenamic acid and diclofenac sodium in osteoarthritis of the weight bearing joints: a double blind comparison. Br. J. Clin. Pract. 39(4), 135-139 (1985).
88. Hébert JG, Le Morvan P, Bourgouin J. Double-blind comparison of ketoprofen and mefenamic acid in the treatment of primary dysmenorrhea. Clin. Ther. 8(3), 329-335 (1986).
89. Serfaty D. A comparative crossover study of piroxicam vs. mefenamic acid and diclofenac in France. Acta Obstet. Gynecol. Scand. Suppl. 138, 19-20 (1986).
90. de Mello NR, Baracat EC, Tomaz G et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet. Gynecol. Scand. 83(7), 667-673 (2004).
91. Anderson AB, Haynes PJ, Fraser IS, Turnbull AC. Trial of prostaglandinsynthetase inhibitors in primary dysmenorrhoea. Lancet 1(8060), 345-348 (1978).
92. Nor Azlin MI, Maryasalwati I, Norzilawati N, Mahdy ZA, Jamil MA, Zainul Rashid MR. The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: a randomized comparative trial. J. Obstet. Gynaecol. 28(9), 424-426 (2008).
93. Ozgoli G, Goli M, Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J. Altern. Complement. Med. 15(2), 129-132 (2009).
94. Pulkkinen MO. Suppression of uterine activity by prostaglandin synthetase inhibitors. Acta Obstet. Gynecol. Scand. Suppl. 87, 39-43 (1979).
95. Sanger GJ, Bennett A. Fenamates may antagonize the actions of prostaglandin endoperoxides in human myometrium. Br. J. Clin. Pharmacol. 8(5), 479-482 (1979).
96. Ranong CN, Sukcharoen N. Analgesic effect of etoricoxib in secondary dysmenorrhea: a randomized, double-blind, crossover, controlled trial. J. Reprod. Med. 52(11), 1023-1029 (2007).
97. Guillebaud J, Anderson ABM, Turnbull AC. Reduction by mefenamic acid of increased menstrual blood loss associated with intrauterine contraception. Br. J. Obstet. Gynaecol. 85(1), 53-62 (1978).
98. Pedron N, Lozano M, Aznar R. Treatment of hypermenorrhea with mefenamic acid in women using IUDs. Contracept. Deliv. Syst. 3(2), 135-139 (1982).
99. Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception 70(4), 277-279 (2004).
100. Nagele F, Lockwood G, Magos AL. Randomised placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilot study. Br. J. Obstet. Gynaecol. 104(7), 842-844 (1997).
101. Jareethum R, Suksompong S, Petyim S, Prechapanich J, Laokirkkiat P, Choavaratana R. Efficacy of mefenamic acid and hyoscine for pain relief during saline infusion sonohysterography in infertile women: a double blind randomized controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 155(2), 193-198 (2011).
102. Sharma JB, Aruna J, Kumar P, Roy KK, Malhotra N, Kumar S. Comparison of efficacy of oral drotaverine plus mefenamic acid with paracervical block and with intravenous sedation for pain relief during hysteroscopy and endometrial biopsy. Indian J. Med. Sci. 63(6), 244-252 (2009).
103. Buppasiri P, Tangmanowutikul S, Yoosuk W. Randomized controlled trial of mefenamic acid vs paracervical block for relief of pain for outpatient uterine curettage. J. Med. Assoc. Thai. 88(7), 881-885 (2005).
104. Mital P, Garg S, Khuteta RP, Khuteta S, Mital P. Mefenamic acid in prevention of premature labour. J. R. Soc. Health 112(5), 214-216 (1992).
105. Macintyre IM, Fink P, McGrouther R, Spence A, Zarifa Z. A single-blind study of naproxen sodium and mefenamic acid in minor trauma. Scott. Med. J. 29(4), 234-237 (1984).
106. Stableforth PG. Mefenamic acid and dextropropoxyphene with paracetamol as analgesics in the accident department. Curr. Med. Res. Opin. 5(2), 189-191 (1977).
107. Sleet RA, Khan MA. Comparative study of mefenamic acid and dextropropoxyphene plus paracetamol in an accident and emergency department. Curr. Med. Res. Opin. 7(2), 77-84 (1980).
108. Yates DW, Laing GS, Peters K, Kumar K. Mild analgesics and the accident and emergency department -cost and safety more important than potency? Arch. Emerg. Med. 1(4), 197-203 (1984).
109. Barrington R. Single-blind study of diflunisal versus mefenamic acid in the treatment of pain after Colles' fracture. Curr. Med. Res. Opin. 6(9), 630-633 (1980).
110. Haig G. A double-blind comparison of mefenamic acid and piroxicam in acute soft tissue injuries. Curr. Med. Res. Opin. 10(10), 645-651 (1988).
111. Sweetman BJ, Baig A, Parsons DL. Mefenamic acid, chlormezanone- paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain. Br. J. Clin. Pract. 41(2), 619-624 (1987).
112. Evans DP, Burke MS, Newcombe RG. Medicines of choice in low back pain. Curr. Med. Res. Opin. 6(8), 540-547 (1980).
113. Jaffe GV, Grimshaw JJ, Owen-Reece AR. A controlled study of mefenamic acid and sulindac in osteoarthritis. Br. J. Clin. Pract. 36, 55-58 (1982).
114. Barnard-Jones K, Davies RW, Lalla O, Mann PG, Welch RB. Mefenamic acid versus ibuprofen in osteoarthritis -a double-blind cross-over study. Br. J. Clin. Pract. 40(12), 528-531 (1986).
115. Stewart I, Thomas A. Mefenamic acid compared with diclofenac sodium in elderly patients with osteoarthritis. Br. J. Clin. Pract. 42(8), 316-320 (1988).
116. Ferris JE, Pigott PV. Evaluation of mefenamic acid and flufenamic acid in clinical pain. Ann. Phys. Med. 84-86 (1966).
117. Buchmann E. Mefenamic acid compared with indomethacin and placebo in osteoarthritis. Ann. Phys. Med. 119-125 (1966).
118. Cahill WJ, Hill RD, Jessop J, Kendall PH. Trial of mefenamic acid. Ann. Phys. Med. 8, 26-29 (1965).
119. Rowe NH, Shekter MA, Turner JL, Spencer J, Dowson J, Petrick TJ. Control of pain resulting from endodontic therapy: a double-blind, placebo-controlled study. Oral Surg. Oral Med. Oral Pathol. 50(3), 257-263 (1980).
120. Rowe NH, Cudmore CL, Turner JL. Control of pain by mefenamic acid following removal of impacted molar. Oral Surg. 51(6), 575-580 (1981).
121. Or S, Bozkurt A. Analgesic effect of aspirin, mefenamic acid and their combination in post-operative oral surgery pain. J. Int. Med. Res. 16(3), 167-172 (1988).
122. Lownie JF, Lownie MA, Reinach SG. Comparison of the safety and efficacy of a combination analgesic Myprodol and Ponstan in the treatment of dental pain. J. Dent. Assoc. S. Afr. 47(9), 403-406 (1992).
123. Ohnishi M, Kawai T, Ogawa N. Doubleblind comparison of piroxicam and mefenamic acid in the treatment of oral surgical pain. Eur. J. Rheumatol. Inflamm. 6(3), 253-258 (1983).
124. Hall DW. Migraine: mefenamic acid (Ponstan) in the treatment of attacks. J. R. Coll. Gen. Practit. 15(4), 321-324 (1968).
125. Hirata K, Tatsumoto M, Araki N et al. Multi-center randomized control trial of etizolam plus NSAID combination for tension-type headache. Intern. Med. 46(8), 467-472 (2007).
126. Al-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur. J. Med. Res. 5(4), 176-182 (2000).
127. Peatfield RC, Petty RG, Rose FC. Double blind comparison of mefenamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia 3(2), 129-134 (1983).
128. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol. Scand. 73(5), 490-492 (1986).
129. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17), 1346-1353 (2012).
130. Vaidya AB, Sheth MS, Manghani KK, Shroff P, Vora KK, Sheth UK. Double blind trial of mefenamic acid, aspirin and placebo in patients with post-operative pain. Indian J. Med. Sci. 28(12), 532-536 (1974).
131. Harrison RF, Brennan M. Comparison of two formulations of lignocaine spray with mefenamic acid in the relief of post-episiotomy pain: a placebo-controlled study. Curr. Med. Res. Opin. 10(6), 375-379 (1987).
132. Wu WC, Hsu KH, Chen TL et al. Interventions for relieving pain associated with panretinal photocoagulation: a prospective randomized trial. Eye (Lond). 20(6), 712-719 (2006).
133. General Practitioner Research Group. Mefenamic acid as an analgesic. Practitioner 204, 857-860 (1970).
134. Kater RM. Double-blind evaluation of the analgesic and toxic effects of flufenamic acid and mefenamic acid in patients with chronic pain. Med. J. Aust. 1(20), 848-851 (1968).
135. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. A comparative evaluation of marketed analgesic drugs. N. Engl. J. Med. 286(15), 813-815 (1972).
136. Myles AB, Bacon PA, Williams KA. Mefenamic acid in rheumatoid arthritis. Ann. Rheum. Dis. 26(6), 494-498 (1967).
137. Stephens WH, El-Ghobarey AF, Macleod MM, Buchanan WW. A double-blind, crossover trial of mefenamic acid, sulindac and flurbiprofen in rheumatoid arthritis. Curr. Med. Res. Opin. 5(10), 754-758 (1979).
138. Mavrikakis ME, MacLeod M, Buchanan WW, Hernandez LA, Rennie JA. Mefenamic acid: an under-rated antirheumatic? Curr. Med. Res. Opin. 4(8), 535-539 (1977).
139. Leslie RD. Mefenamic acid compared with ibuprofen in the treatment of rheumatoid arthritis. J. Int. Med. Res. 5(3), 161-163 (1977).
140. Stockman A, Varigos GA, Muirden KD. Comparison of effectiveness of mefenamic acid and ibuprofen in treatment of rheumatoid arthritis. Med. J. Aust. 2(22), 819-821 (1976).
141. Lee P, Anderson JA, Miller J, Webb J, Buchanan WW. Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. J. Rheumatol. 3(3), 283-294 (1976).
142. Keinänen S, Similä S, Kouvalainen K. Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid. Eur. J. Clin. Pharmacol. 13(5), 331-344 (1978).
143. Weiss CF, Harris ST, Barrow WB, Buchanan RA. Mefanamic acid -an antipyretic for use in children. J. Pediatr. 72(6), 867-870 (1968).
144. Salzberg R, Giambonini S, Maurizio M, Roulet D, Zahn J, Monti T. A doubleblind comparison of nimesulide and mefenamic acid in the treatment of acute upper respiratory tract infections in children. Drugs 46(Suppl. 1), 208-211 (1993).
145. Ito K, Niida Y, Sato J, Owada E, Ito K, Umetsu M. Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus. Acta Paediatr. Jpn 36(4), 387-391 (1994).
146. Uchiyama A, Nagasawa H, Yamamoto Y et al. Clinical aspects of very-low-birthweight infants showing reopening of ductus arteriosus. Pediatr. Int. 53(3), 322-327 (2011).
147. Shimada S, Kasai T, Konishi M, Fujiwara T. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J. Pediatr. 125(2), 270-277 (1994).
148. Sakhalkar VS, Merchant RH. Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin. Indian Pediatr. 29(3), 313-318 (1992).
149. Sato J, Kudo N, Owada E et al. Urinary excretion of mefenamic acid and its metabolites including their esterglucuronides in preterm infants undergoing mefenamic acid therapy. Biol. Pharm. Bull. 20(4), 443-445 (1997).
150. Menahem S. Administration of prostaglandin inhibitors to the mother; the potential risk to the fetus and neonate with duct-dependent circulation. Reprod. Fertil. Dev. 3(4), 489-494 (1991).
151. Adverse Drug Reactions Advisory Committee. Premature closure of the fetal ductus arteriosus after maternal use of non-steroidal anti-inflammatory drugs. Med. J. Aust. 169, 270-271 (1998).
152. Kordansky D, Adkinson NF Jr, Norman PS, Rosenthal RR. Asthma improved by nonsteroidal anti-inflammatory drugs. Ann. Intern. Med. 88(4), 508-511 (1978).
153. Szczeklik A, Gryglewski RJ, Nizankowska E. Asthma relieved by aspirin and by other cyclo-oxygenase inhibitors. Thorax 33(5), 664-665 (1978).
154. Jackson RH, Raymer WJ, Etter RL. An evaluation of Ponstel® (mefenamic acid) in chronic bronchial asthma and pulmonary emphysema. J. Kansas Med. Soc. 474-478 (1968).
155. LeBow Jr. Successful treatment of chronic urticaria with mefenamic acid. J. Fam. Pract. 17(5), 915-6, 920 (1983).
156. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev. 2, CD006378 (2012).
157. Holmes EL. Experimental observations on flufenamic, mefenamic, and meclofenamic acids. IV. Toleration by normal human subjects. Ann. Phys. Med. 36-49 (1966).
158. Barnardo DE, Currey HL, Mason RM, Fox WR, Weatherall M. Mefenamic acid and flufenamic acid compared with aspirin and phenylbutazone in rheumatoid arthritis. Br. Med. J. 2(5509), 342-343 (1966).
159. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirinsensitive patients. Br. Med. J. 1(5949), 67-69 (1975).
160. Morales MC, Basomba A, Villalmanzo IG, Peláez A, Campos A, Guerrero M. Crossed tolerance to pyrazolines, mephenamic acid, and glafenine in A. S. A.-triad patients desensitized to aspirin. J. Allergy Clin. Immunol. 75(4), 528 (1985).
161. Fernandez-Rivas M, de la Hoz B, Cuevas M, Davila I, Quirce S, Losada E. Hypersensitivity reactions to anthranilic acid derivatives. Ann. Allergy 71(6), 515-518 (1993).
162. Couto M, Duarte C, Geraldes L, Inês L, Malcata A. Anaphylaxis to mefenamic acid in a patient with new onset of systemic lupus erythematosus. Allergol. Immunopathol. (Madr.) 38(4), 224-226 (2010).
163. Leong LL. A case of cardiac arrest following oral 250 mg. mefenamic acid. Med. J. Malaysia 30(3), 229-237 (1976).
164. Galati G, Tafazoli S, Sabzevari O, Chan TS, O'Brien PJ. Idiosyncratic NSAID drug induced oxidative stress. Chem. Biol. Interact. 142(1-2), 25-41 (2002).
165. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 156(3), 385-391 (1997).
166. Tsang MW, Tsang KY, Wong WK. The use of recombinant human epidermal growth factor (rhEGF) in a gentleman with drug-induced Steven Johnson syndrome. Dermatol. Online J. 10(1), 25 (2004).
167. Shepherd AN, Ferguson J, Bewick M, Bouchier IA. Mefenamic acid-induced bullous pemphigoid. Postgrad. Med. J. 62(723), 67-68 (1986).
168. Sakellariou G, Koukoudis P, Karpouzas J et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int. J. Artif. Organs 14(10), 634-638 (1991).
169. Jin K, Nakano H, Akasaka E et al. Linear immunoglobulin A bullous dermatosis possibly induced by mefenamic acid. J. Dermatol. 37(3), 269-271 (2010).
170. Handisurya A, Moritz KB, Riedl E, Reinisch C, Stingl G, Wöhrl S. Fixed drug eruption caused by mefenamic acid: a case series and diagnostic algorithms. J. Dtsch. Dermatol. Ges. 9(5), 374-378 (2011).
171. Watson A, Watt G. Fixed drug eruption to mefenamic acid. Australas. J. Dermatol. 27(1), 6-7 (1986).
172. Whiting PH, Tisocki K, Hawksworth GM. Human renal medullary interstitial cells and analgesic nephropathy. Ren. Fail. 21(3-4), 387-392 (1999).
173. Carlton WW, Engelhardt JA. Experimental renal papillary necrosis in the Syrian hamster. Food Chem. Toxicol. 27(5), 331-340 (1989).
174. Rahman A, Segasothy M, Samad SA, Zulfiqar A, Rani M. Analgesic use and chronic renal disease in patients with headache. Headache 33(8), 442-445 (1993).
175. Shipton EA, Müller FO. Severe mefenamic acid poisoning. A case report. S. Afr. Med. J. 67(20), 823-824 (1985).
176. Robertson CE, Ford MJ, Van Someren V, Dlugolecka M, Prescott LF. Mefenamic acid nephropathy. Lancet 2(8188), 232-233 (1980).
177. Abt AB, Oh JY, Huntington RA, Burkhart KK. Chinese herbal medicine induced acute renal failure. Arch. Intern. Med. 155(2), 211-212 (1995).
178. Jenkins DA, Harrison DJ, MacDonald MK, Winney RJ. Mefenamic acid nephropathy: an interstitial and mesangial lesion. Nephrol. Dial. Transplant. 3(2), 217-220 (1988).
179. Woods KL, Michael J. Mefenamic acid nephropathy. Br. Med. J. (Clin. Res. Ed.) 282(6274), 1471 (1981).
180. Boletis J, Williams AJ, Shortland JR, Brown CB. Irreversible renal failure following mefenamic acid. Nephron 51(4), 575-576 (1989).
181. Brix AE. Renal papillary necrosis. Toxicol. Pathol. 30(6), 672-674 (2002).
182. Segasothy M, Thyaparan A, Kamal A, Sivalingam S. Mefenamic acid nephropathy. Nephron 45(2), 156-157 (1987).
183. Villanueva L, Pelissier T, Delgado S, Paeile C. Electroencephalographic affects of an anti-inflammatory analgesic: mefenamic acid. Res. Commun. Chem. Pathol. Pharmacol. 26(2), 253-262 (1979).
184. Cremona-Barbaro A. Extrapyramidal symptoms following mefenamic acid. J. R. Soc. Med. 76(5), 435 (1983).
185. Young RJ. Mefenamic acid poisoning and epilepsy. Br. Med. J. 2(6191), 672 (1979).
186. Gössinger H, Hruby K, Haubenstock A, Jung M, Zwerina N. Coma in mefenamic acid poisoning. Lancet 2(8294), 384 (1982).
187. Gosche JR, Garrison RN. Prostaglandins mediate the compensatory responses to hemorrhage in the small intestine of the rat. J. Surg. Res. 50(6), 584-588 (1991).
188. Lane AZ, Holmes EL, Moyer CE. Gastrointestinal bleeding in normal subjects: a comparison of aspirin and mefenamic acid. J. New Drugs 40, 333-336 (1964).
189. Skyring A, Bhanthumnavin K. Gastrointestinal bleeding: a comparison of mefenamic acid and aspirin. Med. J. Aust. 1(12), 601-603 (1967).
190. Katsinelos P, Dimiropoulos S, Vasiliadis T, Fotiadis G, Xiarchos P, Eugenidis N. Oesophageal ulceration associated with ingestion of mefenamic acid capsules. Eur. J. Gastroenterol. Hepatol. 11(12), 1431-1432 (1999).
191. Fujii A, Kuboyama N, Kobayashi S, Namiki Y, Tamura T. Time-course study of gastric damages in rats by anti-inflammatory drugs using a gastroscope and its quantification. Jpn J. Pharmacol. 48(3), 317-322 (1988).
192. Kaump DH. Experimental observations on flufenamic, mefenamic, and meclofenamic acids. II. Toxicology in animals. Ann. Phys. Med. Suppl. 16-23 (1966).
193. Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol. Drug Saf. 20(7), 763-771 (2011).
194. Trewin VF, Lawrence CJ, Rae SA, Veitch GB. Development and use of a gastropathy index for ranking the safety of non-steroidal anti-inflammatory drugs in the elderly. J. Clin. Pharm. Ther. 19(3), 209-214 (1994).
195. Elliott G, Whited BA, Purmalis A et al. Effect of 16,16-dimethyl PGE2 on renal papillary necrosis and gastrointestinal ulcerations (gastric, duodenal, intestinal) produced in rats by mefenamic acid. Life Sci. 39(5), 423-432 (1986).
196. Batt M. Non-coeliac flat jejunal mucosa. Gut 30 Spec. No., 67-68 (1989).
197. Isaacs PE, Sladen GE, Filipe I. Mefenamic acid enteropathy. J. Clin. Pathol. 40(10), 1221-1227 (1987).
198. Peacey SR, Walls WD. Steatorrhea and sub-total villous atrophy complicating mefenamic acid therapy. BJCP 46, 211 (1992).
199. Chadwick RG, Hossenbocus A, Colin-Jones DG. Steatorrhea complicating therapy with mefenamic acid. BMJ 397 (1976).
200. Marks JS, Gleeson MH. Steatorrhea complicating therapy with mefenamic acid. BMJ 4, 442 (1975).
201. Panicker JN, Philip J. An unusual cause of colitis. J. Postgrad. Med. 53(2), 145 (2007).
202. Ravi S, Keat AC, Keat EC. Colitis caused by non-steroidal anti-inflammatory drugs. Postgrad. Med. J. 62(730), 773-776 (1986).
203. Phillips MS, Fehilly B, Stewart S, Dronfield MW. Enteritis and colitis associated with mefenamic acid. BMJ 287, 1626 (1983).
204. Tanner AR, Raghunath AS. Colonic inflammation and nonsteroidal antiinflammatory drug administration. An assessment of the frequency of the problem. Digestion 41(2), 116-120 (1988).
205. de Sanctis S, Qureshi T, Stebbing JF. Clinical and pathological overlap in nonsteroidal anti-inflammatory drug-related small bowel diaphragm disease and the neuromuscular and vascular hamartoma of the small bowel. Am. J. Surg. Pathol. 25(4), 539-541 (2001).
206. Allen CN, Harpur ES, Gray TJB, Hirst BH. Toxic effects of non-steroidal anti-inflammatory drugs in a human intestinal epithelial cell line (HCT-8) as assessed by the MTT and neutral red assays. Toxicol. In Vitro 5, 183-191 (1991).
207. Jurima-Romet M, Crawford K, Huang HS. Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicol. In Vitro 8(1), 55-66 (1994).
208. Somchit N, Sanat F, Gan EH, Shahrin IA, Zuraini A. Liver injury induced by the non-steroidal anti-inflammatory drug mefenamic acid. Singapore Med. J. 45(11), 530-532 (2004).
209. Chan JC, Lai FM, Critchley JA. A case of Stevens-Johnson syndrome, cholestatic hepatitis and haemolytic anaemia associated with use of mefenamic acid. Drug Saf. 6(3), 230-234 (1991).
210. Farid NR, Johnson RJ, Low WT. Blood-transfusion in the presence of haemolytic anaemia. Lancet 2(7720), 382 (1971).
211. Scott GL, Myles AB, Bacon PA. Autoimmune haemolytic anaemia and mefenamic acid therapy. Br. Med. J. 3(5617), 534-535 (1968).
212. Jackson JM, Quinlan J, Goatcher P. Mefenamic acid-induced haemolytic anaemia. BMJ 2, 297-298 (1970).
213. Ahmad I, Suhail M. Protective role of vitamin E on mefenamic acid-induced alterations in erythrocytes. Biochemistry Mosc. 67(8), 945-948 (2002).
214. Chan TYK. Adverse interactions between warfarin and nonsteroidal anti-inflammatory drugs: mechanisms, clinical significance, and avoidance. Ann. Pharmacother. 29, 1274-1283 (1995).
215. Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 116(1), 91-97 (2009).
216. Burns A, Young RE. Mefenamic acid induced leucopenia in the elderly. Lancet 2(8393), 46 (1984).
217. Muroi K, Ito M, Sasaki R, Suda T, Sakamoto S, Miura Y. Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor. Lancet 2(8653), 55 (1989).
218. Kankaanranta H, Moilanen E, Vapaatalo H. Effects of non-steroidal anti-inflammatory drugs on polymorphonuclear leukocyte functions in vitro: focus on fenamates. Naunyn Schmiedebergs Arch. Pharmacol. 350(6), 685-691 (1994).
219. Latham BA, Radcliff F, Robinson RG. The effect of mefenamic acid and flufenamic acid on plasma uric acid levels. Ann. Phys. Med. 8(7), 242-243 (1966).
220. Vishwakarma P, Raman GV, Sathyan P. Mefenamic acid-induced bilateral transient myopia, secondary angle closure glaucoma and choroidal detachment. Indian J. Ophthalmol. 57(5), 398-400 (2009).
221. Gerbig AW, Paredes B, Hunziker T. Multiple IgA autoantibodies associated with mefenamic acid. Ann. Intern. Med. 129(7), 588-589 (1998).
222. O'Hagan AH, Irvine AD, Allen GE, Walsh M. Pseudoporphyria induced by mefenamic acid. Br. J. Dermatol. 139(6), 1131-1132 (1998).
223. Montenegro MA, Palomino H. Induction of cleft palate in mice by inhibitors of prostaglandin synthesis. J. Craniofac. Genet. Dev. Biol. 10(1), 83-94 (1990).
224. Halbert DR. Menstrual delay and dysfunctional uterine bleeding associated with antiprostaglandin therapy for dysmenorrhea. J. Reprod. Med. 28(9), 592-594 (1983).
225. McMurray JJ, Northridge DB, Abernethy VA, Lawson AAH. Trends in analgesic self-poisoning in West-Fife, 1971-1985. Quart. J. Med. 246, 835-843 (1987).
226. Prescott LF. Clinical features and management of analgesic poisoning. Hum. Toxicol. 3, S75-S84 (1984).
227. Court H, Volans GN. Poisoning after overdose with non-steroidal anti-inflammatory drugs. Adverse Drug React. Acute Poisoning Rev. 3(1), 1-21 (1984).
228. Ahmed MK. Drug-associated admissions to a district hospital in Saudi Arabia. J. Clin. Pharm. Ther. 22, 61-66 (1997).
229. Hendrickse MT. Mefenamic acid overdose mimicking brainstem stroke. Lancet 2(8618), 1019 (1988).
230. Turnbull AJ, Campbell P, Hughes JA. Mefenamic acid nephropathy -acute renal failure in overdose. BMJ 296, 646 (1988).
231. Robson RH, Balali M, Critchley J, Proudfoot AT, Prescott L. Mefenamic acid poisoning and epilepsy. Br. Med. J. 2(6202), 1438 (1979).
232. McKillop G, Canning GP. A case of intravenous and oral mefenamic acid poisoning. Scott. Med. J. 32(3), 81-82 (1987).
233. Vale JA, Meredith TJ. Acute poisoning due to non-steroidal anti-inflammatory drugs: clinical features and management. Med. Toxicol. 1, 12-31 (1986).
234. Wang LH, Lee CS, Marbury TC. Hemodialysis of mefenamic acid in uremic patients. Am. J. Hosp. Pharm. 37(7), 956-958 (1980).
235. El-Bahie N, Allen EM, Williams J, Routledge PA. The effect of activated charcoal and hyoscine butylbromide alone and in combination on the absorption of mefenamic acid. Br. J. Clin. Pharmacol. 19(6), 836-838 (1985).
236. Dasgupta A, Emerson L. Interaction of valproic acid with nonsteroidal anti-inflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Ther. Drug Monitor. 18, 654-659 (1996).
237. Agar JW. Cyclosporin A and mefenamic acid in a renal transplant patient. Aust. N. Z. J. Med. 21(5), 784-785 (1991).
238. MacDonald J, Neale TJ. Toxic interaction of lithium carbonate and mefenamic acid. BMJ 297(6659), 1339 (1988).
239. Shelley RK. Lithium toxicity and mefenamic acid. Br. J. Psych. 151, 847-848 (1987).
240. Yokobori S, Yokota H, Yamamoto Y. Pediatric posterior reversible leukoencephalopathy syndrome and NSAID-induced acute tubular interstitial nephritis. Pediatr. Neurol. 34(3), 245-247 (2006).
241. Sinniah R, Lye WC. Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid. Clin. Nephrol. 55(3), 254-258 (2001).